Estudios de costo-efectividad en cáncer.

Milton Lombana

doi:10.51643/22562915.308

Estudios de costo-efectividad en cáncer.

Cost-effectiveness studies in cancer.

Publicado 2012-09-01

Abrir | Descargar

PDF FLIP

Número

Vol. 1 Núm. 3 (2012): Septiembre

Sección

Editorial

Cómo citar

Estudios de costo-efectividad en cáncer.

Rev. colomb. hematol. oncol. [Internet]. 2012 Sep. 1 [cited 2025 Jan. 6];1(3):10-2. Disponible en: https://doi.org/10.51643/22562915.308

DOI

https://doi.org/10.51643/22562915.308

Dimensions

PlumX

Licencia

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Milton Lombana

Universidad Militar Nueva Granada

Mostrar biografía de los autores

Milton Lombana,

Departamento de Oncología y Hematología, Universidad Militar Nueva Granada, Hospital Militar Central (Bogotá, Colombia).

Visitas del artículo 101 | Visitas PDF 196

Wagstaff A, Culyer AJ. Four decades of health economics through a bibliometric lens. J Health Econ. 2012;31(2):406-39.
Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martín SG. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics. 2009;27(11):919-29.
Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma: Part I--an updated review. Pharmacoeconomics. 2011;29(4):315-29.
Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health. 2010;13(6):837-45.
Godoy J, Cardona AF, Cáceres H, Otero JM, Luján M, Lopera D, et al. First line treatment for metastatic renal cell carcinoma in Colombia: a cost-effectiveness analysis. (In press).
Paz-Ares L, Del Muro J, Grande E, Díaz S. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J Clin Pharm Ther. 2010;35(4):429-38.
Coon JT, Hoyle M, Green C, Liu Z, Welch K, Moxham T, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14(2):1-184.
Duh MS, Dial E, Choueiri T, Fournier AA, Antras L, Rodermund D, et al. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin. 2009;25(8):2081-90.
Aller E, Maroto P, Kreif N, González Larriba JL, López-Brea M, Castellano D, et al. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011;13(12):869-77.
Choueiri T, McDermott D, Duh M, Sarda S, Neary M, Oh WK. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study. Urol Oncol. 2010. [Epub ahead of print].
Wu B, Dong B, Xu Y, Zhang Q, Shen J, Chen H, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost effectiveness analysis in a health resource-limited setting. PLoS One. 2012;7(3):e32530.
Benedict A, Figlin RA, Sandström P, Harmenberg U, Ullén A, Charbonneau C, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. 2011;108(5):665-72.
Remák E, Charbonneau C, Négrier S, Kim S, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26(24):3995-4000.
Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol. 2012;30(8):871-7.
Rimawi M, Hilsenbeck SG. Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? J Clin Oncol. 2012;30(4):453-8.
Alemao E, Rajagopalan S, Yang S, Curiel RE, Purvis J, Al MJ. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. J Med Econ. 2011;14(2):245-52.
Mansley EC, Elbasha EH, Teutsch SM, Berger ML. The decision to conduct a head-to-head comparative trial: a game-theoretic analysis. Med Decis Making. 2007;27(4):364-79.
Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force Report--Part I. Value Health. 2010;13(1):3-7.